The CenterWatch Monthly
Group seeks greater diversity in clinical research…
In 2006, a trial led to a “black box warning label” for an asthma medication found to have a disproportionally increased death rate. It revealed that respiratory-related deaths occurred four times more often in African-Americans who took the drug.
In 2007, additional studies showed that long-acting beta-antagonist drugs worsen asthma due to down-regulation of b-adrenergic system as a result of the stimulation of b-receptors. This genotype affects roughly one-sixth of U.S. citizens and may be more prevalent in specific minorities, including African-Americans.
There is greater assurance in the safety and effectiveness of investigational products when there is subgroup data to analyze.
CDCR sites such as Chattanoo- ga Medical Research (CMR) in Tennessee, Advances in Health (AIH) in Houston and AGA Clinical Trials in Miami are increasing diversity through education and awareness development. CMR has partnered with local high schools and colleges to educate students not only about clinical research, but also ca- reer paths within the industry. AIH holds seminars with the Black Nurses Association and participates in community outreach ministries within minority neighborhoods. AGA is active with the American Diabetes Association and participates in local health fairs and events.